PALO ALTO, Calif. / Nov 03, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences:
Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping every person live a life free from cancer. Founded in 2012, Guardant is transforming cancer care by providing critical insights into what drives the disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve patient outcomes across all stages of cancer, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).
| Last Trade: | US$51.00 |
| Daily Change: | 0.82 1.63 |
| Daily Volume: | 811,118 |
| Market Cap: | US$6.300B |
June 03, 2025 May 27, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
